Publications by authors named "Menso J Westerouen van Meeteren"
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
Expert Opin Investig Drugs
February 2020
Article Synopsis
- Nonalcoholic fatty liver disease (NAFLD) starts as simple fat accumulation in the liver and can progress to a more severe condition called nonalcoholic steatohepatitis (NASH), which is linked to metabolic syndrome and increased mortality risks.
- Elafibranor, a drug being developed for treating NAFLD, targets peroxisome proliferator-activated receptors (PPARs) that play a crucial role in managing lipid and insulin metabolism, showing promise in improving conditions associated with NASH like insulin resistance and abnormal lipid levels.
- Though elafibranor has a generally favorable safety profile, it may cause temporary increases in serum creatinine levels, which could be a concern for those with kidney